| Bioactivity | Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM[1]. | ||||||||||||
| Invitro | Vebicorvir (ABI-H0731) demonstrates inhibition of pgRNA, HBeAg, and HBsAg production, with EC50s of 2.68 μM, 4.95 μM, and 7.30 μM, respectively[1].Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis[1]. | ||||||||||||
| In Vivo | After i.v. administration, the drug rapidly distributes and decayes in a biphasic manner in all species tested. Plasma clearance values of ABI-H0731 were 8.05, 10.1, 14.7, and 4.86 ml/min/kg, representing 9, 16, 47, and 11% of liver blood flow, in mouse, rat, dog, and monkey, respectively[1]. | ||||||||||||
| Name | Vebicorvir | ||||||||||||
| CAS | 2090064-66-5 | ||||||||||||
| Formula | C19H12F3N3O4S2 | ||||||||||||
| Molar Mass | 467.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Qi Huang, et al. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20. |
Vebicorvir
CAS: 2090064-66-5 F: C19H12F3N3O4S2 W: 467.44
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) supp
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.